Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
Gavin Giovannoni
Topics & Concepts
MedicineImmunosuppressionOcrelizumabCoronavirus disease 2019 (COVID-19)Multiple sclerosisDiseaseInternal medicineDiabetes mellitusIntensive care medicineImmunologyRituximabInfectious disease (medical specialty)EndocrinologyLymphomaLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research Studies